Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:

Why now is the time to tackle DR-TB

Today's Top Reads Close

Drug-resistant TB (DR-TB) is on the rise with 558,000 new cases a year. It is the only airborne drug-resistant epidemic and responsible for nearly 1/3 of all deaths from antimicrobial resistance (AMR) globally.

A new report by The Economist Intelligence Unit (EIU), and made possible with support from Johnson & Johnson, emphasizes the urgent need for global action to address the growing threat of DR-TB.

Learn more.

Back to top
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.